Company research
ESSA Pharma Inc.
CIK 1633932Updated Sep 27, 2026
Securities
Historical securities (1)
EPIX · NASDAQ · equity · closed Oct 8, 2025EPIX price & chart
Historical security
This listing closed Oct 8, 2025. Live provider charts are shown only for current listings.
About the company
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
In the news
No coverage from other publishers is available.
Financials
FY 2024 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 128,112,003Source | 149,122,131Source | 169,505,295Source | 198,165,818Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 103,709,537Source | 33,701,912Source | 57,076,475Source | 137,825,024Source |
| Assets, CurrentUSD | 127,559,555Source | 148,796,878Source | 169,059,341Source | 197,598,077Source |
| Operating Lease, Right-of-Use AssetUSD | 295,471Source | 68,008Source | 186,499Source | 308,286Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,506,233Source | 3,495,071Source | 2,386,817Source | 4,160,266Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 279,862,420Source | 278,161,537Source | 278,089,136Source | 277,415,176Source |
| Additional Paid in CapitalUSD | 54,810,797Source | 49,047,280Source | 44,043,503Source | 36,442,620Source |
| Retained Earnings (Accumulated Deficit)USD | -208,004,180Source | -179,461,359Source | -152,879,016Source | -117,775,765Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,063,267Source | -2,120,398Source | -2,135,145Source | -2,076,479Source |
| Stockholders' Equity Attributable to ParentUSD | 124,605,770Source | 145,627,060Source | 167,118,478Source | 194,005,552Source |
| Liabilities and EquityUSD | 128,112,003Source | 149,122,131Source | 169,505,295Source | 198,165,818Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,301,027Source | 3,495,071Source | 2,310,399Source | 3,929,663Source |
| Operating Lease, Liability, CurrentUSD | 124,054Source | 80,328Source | 133,834Source | 120,719Source |
| Accounts Payable, CurrentUSD | 2,403,519Source | 2,028,265Source | 954,598Source | 1,425,871Source |
| Operating Lease, Liability, NoncurrentUSD | 205,206Source | 0Source | 76,418Source | 210,251Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 171,690Source | 845,730Source | 807,484Source | 2,062,441Source |
| Short-term InvestmentsUSD | 23,050,582Source | 114,374,489Source | 110,161,029Source | 57,102,159Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -28,542,821Source | -26,582,343Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,538,890Source | 5,007,469Source | 7,888,085Source | 9,476,113Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -22,716,199Source | -19,781,716Source | -28,704,169Source | -25,415,611Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 91,789,210Source | -3,527,149Source | -52,348,394Source | -35,014,766Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 925,510Source | -68,157Source | 252,735Source | 141,990,753Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 70,007,625Source | -23,374,563Source | -80,748,549Source | 81,504,261Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 103,709,537Source | 33,701,912Source | 57,076,475Source | 137,825,024Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | — | — | — |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 51,279Source | -56,115Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | 33,139Source | 6,942Source | 13,305Source | 9,570Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | 0Source | 20,352Source | 107,024Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 3,432Source | 6,529Source | 1,687Source | -16,041Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 0Source | 528Source | -845Source | 0Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | 0Source | 0Source | — |
| General and Administrative ExpenseUSD | 13,214,193Source | 10,811,574Source | 12,544,760Source | 12,884,581Source |
| Income Tax Expense (Benefit)USD | — | 1,600Source | -111,821Source | -34,349Source |
| Net Income (Loss) Attributable to ParentUSD | -28,542,821Source | -26,582,343Source | -35,103,251Source | -36,805,461Source |
| Operating ExpensesUSD | 34,421,017Source | 32,141,046Source | 36,973,752Source | 37,165,790Source |
| Payments of Financing CostsUSD | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 149,999,985Source |
| Proceeds from Stock Options ExercisedUSD | 879,997Source | 0Source | 319,832Source | 1,186,833Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -28,542,821Source | -26,580,743Source | -35,215,072Source | -36,839,810Source |
| Income Tax Expense (Benefit)USD | — | 1,600Source | -111,821Source | -34,349Source |
| Net Income (Loss) Attributable to ParentUSD | -28,542,821Source | -26,582,343Source | -35,103,251Source | -36,805,461Source |
| Earnings Per Share, BasicUSD per share | -0.64Source | -0.6Source | -0.8Source | — |
| Earnings Per Share, DilutedUSD per share | -0.64Source | -0.6Source | -0.8Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,277,050Source | 44,089,557Source | 44,038,241Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 44,277,050Source | 44,089,557Source | 44,038,241Source | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 3,432Source | 6,529Source | 1,687Source | -16,041Source |
| General and Administrative ExpenseUSD | 13,214,193Source | 10,811,574Source | 12,544,760Source | 12,884,581Source |
| Interest and Other IncomeUSD | 5,874,764Source | 5,553,774Source | 1,736,641Source | — |
| Investment Income, NetUSD | -500,148Source | -374Source | — | — |
| Operating ExpensesUSD | 34,421,017Source | 32,141,046Source | 36,973,752Source | 37,165,790Source |
| Research and Development ExpenseUSD | 21,206,824Source | 21,322,530Source | 24,415,246Source | 24,258,989Source |